{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T03:50:37Z","timestamp":1793677837967,"version":"4.5.1"},"reference-count":58,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.antiviral.2026.106342","type":"journal-article","created":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T07:10:58Z","timestamp":1768461058000},"page":"106342","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Therapeutic intranasal delivery of NanoSTING provides broad protection against seasonal and highly pathogenic influenza strains"],"prefix":"10.1016","volume":"247","author":[{"given":"Ankita","family":"Leekha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate","family":"Reichel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1025-5878","authenticated-orcid":false,"given":"Brett","family":"Hurst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7524-8228","authenticated-orcid":false,"given":"Navin","family":"Varadarajan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2026.106342_bib1","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1038\/nature12306","article-title":"cGAS produces a 2'-5'-linked cyclic dinucleotide second messenger that activates STING","volume":"498","author":"Ablasser","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2026.106342_bib2","first-page":"1","article-title":"STING signaling and host defense against microbial infection","volume":"51","author":"Ahn","year":"2019","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.antiviral.2026.106342_bib3","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.addr.2012.09.037","article-title":"Liposomal drug delivery systems: from concept to clinical applications","volume":"65","author":"Allen","year":"2013","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.antiviral.2026.106342_bib4","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1053\/j.seminoncol.2004.08.001","article-title":"Advantages of liposomal delivery systems for anthracyclines","volume":"31","author":"Allen","year":"2004","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.antiviral.2026.106342_bib5","doi-asserted-by":"crossref","DOI":"10.1186\/ar3089","article-title":"Liposomal encapsulation enhances and prolongs the anti-inflammatory effects of water-soluble dexamethasone phosphate in experimental adjuvant arthritis","volume":"12","author":"Anderson","year":"2010","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.antiviral.2026.106342_bib6","doi-asserted-by":"crossref","first-page":"7913","DOI":"10.1016\/j.vaccine.2011.08.076","article-title":"Predictors of immune response and reactogenicity to AS03B-adjuvanted split virion and non-adjuvanted whole virion H1N1 (2009) pandemic influenza vaccines","volume":"29","author":"Andrews","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.antiviral.2026.106342_bib7","doi-asserted-by":"crossref","first-page":"9538","DOI":"10.1073\/pnas.1321656111","article-title":"Multiannual forecasting of seasonal influenza dynamics reveals climatic and evolutionary drivers","volume":"111","author":"Axelsen","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.antiviral.2026.106342_bib8","doi-asserted-by":"crossref","DOI":"10.3390\/microorganisms11010183","article-title":"Influenza treatment: limitations of antiviral therapy and advantages of drug combination therapy","volume":"11","author":"Batool","year":"2023","journal-title":"Microorganisms"},{"key":"10.1016\/j.antiviral.2026.106342_bib9","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1150705","article-title":"cGAMP the travelling messenger","volume":"14","author":"Blest","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.antiviral.2026.106342_bib10","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.3389\/fimmu.2019.01605","article-title":"Innovative mucosal vaccine formulations against influenza A virus infections","volume":"10","author":"Calzas","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.antiviral.2026.106342_bib11","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1136\/bmj.326.7401.1235","article-title":"Effectiveness of neuraminidase inhibitors in treatment and prevention of influenza A and B: systematic review and meta-analyses of randomised controlled trials","volume":"326","author":"Cooper","year":"2003","journal-title":"Bmj"},{"key":"10.1016\/j.antiviral.2026.106342_bib12","doi-asserted-by":"crossref","first-page":"3864","DOI":"10.1038\/ncomms4864","article-title":"Pathogenic potential of interferon \u03b1\u03b2 in acute influenza infection","volume":"5","author":"Davidson","year":"2014","journal-title":"Nat. Commun."},{"key":"10.1016\/j.antiviral.2026.106342_bib13","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s12985-020-01348-4","article-title":"Influenza a virus antagonizes type I and type II interferon responses via SOCS1-dependent ubiquitination and degradation of JAK1","volume":"17","author":"Du","year":"2020","journal-title":"Virol. J."},{"issue":"Suppl. 2","key":"10.1016\/j.antiviral.2026.106342_bib14","first-page":"ii11","article-title":"Oseltamivir in seasonal influenza: cumulative experience in low- and high-risk patients","volume":"65","author":"Dutkowski","year":"2010","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.antiviral.2026.106342_bib15","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1136\/ard.2005.036434","article-title":"Vaccination against influenza in rheumatoid arthritis: the effect of disease modifying drugs, including TNF alpha blockers","volume":"65","author":"Fomin","year":"2006","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.antiviral.2026.106342_bib16","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.cytogfr.2015.01.001","article-title":"New perspectives on type I IFNs in cancer","volume":"26","author":"Gajewski","year":"2015","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.antiviral.2026.106342_bib17","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/S0140-6736(24)01307-2","article-title":"Antivirals for treatment of severe influenza: a systematic review and network meta-analysis of randomised controlled trials","volume":"404","author":"Gao","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.antiviral.2026.106342_bib18","article-title":"Innate immune pathway modulator screen identifies STING pathway activation as a strategy to inhibit multiple families of arbo and respiratory viruses","volume":"4","author":"Garcia","year":"2023","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.antiviral.2026.106342_bib19","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1016\/j.vaccine.2024.02.059","article-title":"Real-world effectiveness of seasonal influenza vaccination and age as effect modifier: a systematic review, meta-analysis and meta-regression of test-negative design studies","volume":"42","author":"Guo","year":"2024","journal-title":"Vaccine"},{"key":"10.1016\/j.antiviral.2026.106342_bib20","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1056\/NEJMoa1716197","article-title":"Baloxavir marboxil for uncomplicated influenza in adults and adolescents","volume":"379","author":"Hayden","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2026.106342_bib21","doi-asserted-by":"crossref","first-page":"471","DOI":"10.2165\/00003088-199937060-00003","article-title":"Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802","volume":"37","author":"He","year":"1999","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.antiviral.2026.106342_bib22","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1038\/s41590-019-0408-z","article-title":"Interferon-lambda modulates dendritic cells to facilitate T cell immunity during infection with influenza A virus","volume":"20","author":"Hemann","year":"2019","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.antiviral.2026.106342_bib23","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms10680","article-title":"Influenza A virus targets a cGAS-independent STING pathway that controls enveloped RNA viruses","volume":"7","author":"Holm","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.antiviral.2026.106342_bib24","doi-asserted-by":"crossref","first-page":"949","DOI":"10.3201\/eid2206.151037","article-title":"Debate regarding oseltamivir use for seasonal and pandemic influenza","volume":"22","author":"Hurt","year":"2016","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.antiviral.2026.106342_bib25","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1038\/nature08476","article-title":"STING regulates intracellular DNA-mediated, type I interferon-dependent innate immunity","volume":"461","author":"Ishikawa","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2026.106342_bib26","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.virusres.2015.02.003","article-title":"Influenza virus activation of the interferon system","volume":"209","author":"Killip","year":"2015","journal-title":"Virus Res."},{"key":"10.1016\/j.antiviral.2026.106342_bib27","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.vetmic.2019.06.005","article-title":"A novel I117T substitution in neuraminidase of highly pathogenic avian influenza H5N1 virus conferring reduced susceptibility to oseltamivir and zanamivir","volume":"235","author":"Kode","year":"2019","journal-title":"Vet. Microbiol."},{"issue":"3","key":"10.1016\/j.antiviral.2026.106342_bib28","article-title":"Influenza","volume":"4","author":"Krammer","year":"2018","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.antiviral.2026.106342_bib29","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s12929-023-00942-2","article-title":"Targeting cGAS\/STING signaling-mediated myeloid immune cell dysfunction in TIME","volume":"30","author":"Kumar","year":"2023","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.antiviral.2026.106342_bib30","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S1473-3099(09)70175-6","article-title":"Influenza in immunosuppressed populations: a review of infection frequency, morbidity, mortality, and vaccine responses","volume":"9","author":"Kunisaki","year":"2009","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.antiviral.2026.106342_bib31","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s12979-024-00482-9","article-title":"Age-related STING suppression in macrophages contributes to increased viral load during influenza a virus infection","volume":"21","author":"Lauf","year":"2024","journal-title":"Immun. Ageing"},{"key":"10.1016\/j.antiviral.2026.106342_bib32","doi-asserted-by":"crossref","first-page":"6053","DOI":"10.1038\/s41467-024-50234-y","article-title":"An intranasal nanoparticle STING agonist protects against respiratory viruses in animal models","volume":"15","author":"Leekha","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.antiviral.2026.106342_bib33","doi-asserted-by":"crossref","first-page":"6193","DOI":"10.1038\/s41467-024-50133-2","article-title":"Multi-antigen intranasal vaccine protects against challenge with sarbecoviruses and prevents transmission in hamsters","volume":"15","author":"Leekha","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.antiviral.2026.106342_bib34","doi-asserted-by":"crossref","first-page":"6053","DOI":"10.1038\/s41467-024-50234-y","article-title":"An intranasal nanoparticle STING agonist protects against respiratory viruses in animal models","volume":"15","author":"Leekha","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.antiviral.2026.106342_bib35","doi-asserted-by":"crossref","first-page":"12304","DOI":"10.1128\/JVI.01269-12","article-title":"Type I interferon induction during influenza virus infection increases susceptibility to secondary Streptococcus pneumoniae infection by negative regulation of \u03b3\u03b4 T cells","volume":"86","author":"Li","year":"2012","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2026.106342_bib36","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1038\/nchembio.1661","article-title":"Hydrolysis of 2'3'-cGAMP by ENPP1 and design of nonhydrolyzable analogs","volume":"10","author":"Li","year":"2014","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.antiviral.2026.106342_bib37","article-title":"A review of liposomes as a drug delivery system: current status of approved products, regulatory environments, and future perspectives","volume":"27","author":"Liu","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.antiviral.2026.106342_bib38","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/s41392-023-01451-2","article-title":"Immunosenescence: molecular mechanisms and diseases","volume":"8","author":"Liu","year":"2023","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.antiviral.2026.106342_bib39","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1038\/s41586-019-1553-0","article-title":"SLC19A1 transports immunoreactive cyclic dinucleotides","volume":"573","author":"Luteijn","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2026.106342_bib40","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1093\/cid\/cit725","article-title":"The natural history of influenza infection in the severely immunocompromised vs nonimmunocompromised hosts","volume":"58","author":"Memoli","year":"2014","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.antiviral.2026.106342_bib41","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1056\/NEJMp0900648","article-title":"Global transmission of oseltamivir-resistant influenza","volume":"360","author":"Moscona","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2026.106342_bib42","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abh0319","article-title":"Inhalable Nanobody (PiN-21) prevents and treats SARS-CoV-2 infections in Syrian hamsters at ultra-low doses","volume":"7","author":"Nambulli","year":"2021","journal-title":"Sci. Adv."},{"key":"10.1016\/j.antiviral.2026.106342_bib43","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1186\/s12913-022-08586-y","article-title":"Burden of influenza hospitalization among high-risk groups in the United States","volume":"22","author":"Near","year":"2022","journal-title":"BMC Health Serv. Res."},{"key":"10.1016\/j.antiviral.2026.106342_bib44","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.coviro.2019.01.006","article-title":"Baloxavir marboxil: the new influenza drug on the market","volume":"35","author":"O'Hanlon","year":"2019","journal-title":"Curr. Opin. Virol."},{"key":"10.1016\/j.antiviral.2026.106342_bib45","unstructured":"Organization, W. H. Burden of disease, <https:\/\/www.who.int\/teams\/global-influenza-programme\/surveillance-and-monitoring\/burden-of-disease>(n.d.)."},{"key":"10.1016\/j.antiviral.2026.106342_bib46","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/S1473-3099(11)70295-X","article-title":"Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis","volume":"12","author":"Osterholm","year":"2012","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.antiviral.2026.106342_bib47","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1055\/s-0036-1584801","article-title":"Human influenza virus infections","volume":"37","author":"Peteranderl","year":"2016","journal-title":"Semin. Respir. Crit. Care Med."},{"key":"10.1016\/j.antiviral.2026.106342_bib48","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrmicro.2017.118","article-title":"The evolution of seasonal influenza viruses","volume":"16","author":"Petrova","year":"2018","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.antiviral.2026.106342_bib49","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26010407","article-title":"Alveolar macrophages in viral respiratory infections: sentinels and saboteurs of lung defense","volume":"26","author":"P\u00f6pperl","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.antiviral.2026.106342_bib50","doi-asserted-by":"crossref","first-page":"808","DOI":"10.3109\/23744235.2015.1067369","article-title":"Effectiveness and safety of oseltamivir for treating influenza: an updated meta-analysis of clinical trials","volume":"47","author":"Qiu","year":"2015","journal-title":"Infect. Dis. (Lond.)"},{"key":"10.1016\/j.antiviral.2026.106342_bib51","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1093\/oxfordjournals.aje.a118408","article-title":"Simple method of estimating fifty per cent ENDPOINTS12","volume":"27","author":"Reed","year":"1938","journal-title":"Am. J. Epidemiol."},{"key":"10.1016\/j.antiviral.2026.106342_bib52","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.molcel.2019.05.006","article-title":"SLC19A1 is an importer of the immunotransmitter cGAMP","volume":"75","author":"Ritchie","year":"2019","journal-title":"Mol. Cell"},{"key":"10.1016\/j.antiviral.2026.106342_bib53","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1093\/infdis\/jiae379","article-title":"An update on highly pathogenic avian influenza A(H5N1) virus, clade 2.3.4.4b","volume":"230","author":"Webby","year":"2024","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2026.106342_bib54","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1159\/000508379","article-title":"The role of type I IFNs in influenza: antiviral superheroes or immunopathogenic villains?","volume":"12","author":"Wu","year":"2020","journal-title":"J. Innate Immun."},{"key":"10.1016\/j.antiviral.2026.106342_bib55","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1086\/432008","article-title":"Virulence may determine the necessary duration and dosage of oseltamivir treatment for highly pathogenic A\/Vietnam\/1203\/04 influenza virus in mice","volume":"192","author":"Yen","year":"2005","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2026.106342_bib56","article-title":"Agonists and inhibitors of the cGAS-STING pathway","volume":"29","author":"Yu","year":"2024","journal-title":"Molecules"},{"key":"10.1016\/j.antiviral.2026.106342_bib57","doi-asserted-by":"crossref","first-page":"8091","DOI":"10.1073\/pnas.0711942105","article-title":"Delayed antiviral plus immunomodulator treatment still reduces mortality in mice infected by high inoculum of influenza A\/H5N1 virus","volume":"105","author":"Zheng","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.antiviral.2026.106342_bib58","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.16526","article-title":"Association of lymphopenia with risk of mortality among adults in the US general population","volume":"2","author":"Zidar","year":"2019","journal-title":"JAMA Netw. Open"}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016635422600001X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016635422600001X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T14:11:44Z","timestamp":1771423904000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016635422600001X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":58,"alternative-id":["S016635422600001X"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2026.106342","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic intranasal delivery of NanoSTING provides broad protection against seasonal and highly pathogenic influenza strains","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2026.106342","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"106342"}}